Drug Profile
CY 1748
Alternative Names: CY-1748Latest Information Update: 26 Apr 1999
Price :
$50
*
At a glance
- Originator Epimmune
- Developer Epimmune; Sumitomo Pharmaceuticals
- Class Antithrombotics; Monoclonal antibodies
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Deep vein thrombosis
Most Recent Events
- 26 Apr 1999 Discontinued-Preclinical for Coronary artery restenosis in Japan (Unknown route)
- 26 Apr 1999 Discontinued-Preclinical for Deep vein thrombosis in Japan (Unknown route)
- 26 Apr 1999 Discontinued-Preclinical for Deep vein thrombosis in USA (Unknown route)